GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc covers the month of September 2026. The document serves as a transaction notification regarding share awards to Persons Discharging Managerial Responsibilities (PDMR) and Persons Closely Associated (PCA) under the Company's 2025 Share Value Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £17.9650 per share.
- Transaction Volume: 10,050 shares per transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses two separate share award transactions executed on September 8, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider share awards.
Key Facts for Investor Verification
- Transaction Date: September 8, 2026.
- Recipients: Victoria Whyte (SVP & Company Secretary) and Neil Falkingham (PCA of Lynn Baxter, President, Europe).
- Nature of Transaction: Award of Ordinary Shares under the 2025 Share Value Plan.
- Total Shares Awarded: 20,100 shares (10,050 to each recipient).
- Valuation: Based on a price of £17.9650 per share.